Book An Appointment
Home Our Doctors Dr. Shailesh Talati
Medical Oncology

Dr. Shailesh Talati

Sr. Consultant Medical Oncology

Educational Qualifications

MD

MBBS

Experience

35+ years of experience


Areas of Expertise

Current : Senior Consultant Medical Oncologist KD Hospital, Ahmedabad.


Technical Skills

Since 1984, Shailesh Talati has been practicing as an oncologist and hematologist in Ahmedabad.

He is a pioneer figure in the field of Medical Oncology & is well renowned all over India.

He has been instrumental in the standardisation of the F.N.A.C. procedure for lung cancer at GCRI, Ahmedabad, which has become the accepted diagnostic method for lung cancer.

His areas of special interest include management of various conditions such as Sarcoma, Myeloma & lung cancer.


Experiences in Clinical trials

Phase II trial in triple Receptor negative Breast Cancer Patients

Phase II multi national, Multicenter GCP trial - Blood and bone marrow cancers.

Phase III trial in metastatic Pancreatic cancer (2 Study)

Phase III trial in The Treatment of Bone Metastases in Subjects with Advanced Cancer or Multiple Myeloma

Phase III trial in Lung Cancer

Phase II trial in Metastatic Breast Cancer (3 Study)

Phase II trial in oral Mucositis

Phase III trial in CML

Phase III trial in Metastatic Soft Tissue or Bone Sarcoma

Phase II trial in Lung cancer

Phase III trial for the Prevention of Chemotherapy Induced Nausea and Vomiting Associated with Cisplatin Chemotherapy

Phase III trial in NHL

Phase III trial in carcinoma of Ovary

Phase II/III, Multicentre trial in Relapsed CLL

Phase III, Multicentre trial in CLL

Phase III, multicentre trial in Myeloma

Phase III trial in Prostate Cancer

Phase III trial in Second line Lung Cancer

Phase III trial in Advanced Renal cell carcinoma

Trial of prophylaxis of Neutropenia

Phase II trial of gastrointestinal stromal tumor

Phase III trial of adjuvant Non-Small Cell Lung Cancer

Phase III trial of hormone refractory Prostate Cancer

Phase II study of Colorectal Cancer

Phase II study of Extensive stage Small Cell Lung Cancer